Electric Therapy Traction Table Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 112 |
The global Remicade (Infliximab) and Biosimilar market was valued at US$ 2623.8 million in 2022 and is projected to reach US$ 3781.3 million by 2029, at a CAGR of 5.4% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Brand Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Remicade (Infliximab) and Biosimilar include J & J, Pfizer, Organon and Amgen, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
Infliximab is a monoclonal anti tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis. Avsola, Flixabi, Inflectra, Remicade, Renflexis.
This report aims to provide a comprehensive presentation of the global market for Remicade (Infliximab) and Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Remicade (Infliximab) and Biosimilar. This report contains market size and forecasts of Remicade (Infliximab) and Biosimilar in global, including the following market information:
Global Remicade (Infliximab) and Biosimilar Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Remicade (Infliximab) and Biosimilar Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Remicade (Infliximab) and Biosimilar companies in 2022 (%)
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Remicade (Infliximab) and Biosimilar manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Remicade (Infliximab) and Biosimilar Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Remicade (Infliximab) and Biosimilar Market Segment Percentages, by Type, 2022 (%)
Brand
Biosimilar
Global Remicade (Infliximab) and Biosimilar Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Remicade (Infliximab) and Biosimilar Market Segment Percentages, by Application, 2022 (%)
Ankylosing Spondylitis
Rheumatoid Arthritis
Crohn’s Disease
Other
Global Remicade (Infliximab) and Biosimilar Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Remicade (Infliximab) and Biosimilar Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Remicade (Infliximab) and Biosimilar revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Remicade (Infliximab) and Biosimilar revenues share in global market, 2022 (%)
Key companies Remicade (Infliximab) and Biosimilar sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Remicade (Infliximab) and Biosimilar sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
J & J
Pfizer
Organon
Amgen
Outline of Major Chapters:
Chapter 1: Introduces the definition of Remicade (Infliximab) and Biosimilar, market overview.
Chapter 2: Global Remicade (Infliximab) and Biosimilar market size in revenue and volume.
Chapter 3: Detailed analysis of Remicade (Infliximab) and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Remicade (Infliximab) and Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Remicade (Infliximab) and Biosimilar capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Remicade (Infliximab) and Biosimilar Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Remicade (Infliximab) and Biosimilar Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Remicade (Infliximab) and Biosimilar Overall Market Size
2.1 Global Remicade (Infliximab) and Biosimilar Market Size: 2022 VS 2029
2.2 Global Remicade (Infliximab) and Biosimilar Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Remicade (Infliximab) and Biosimilar Sales: 2018-2029
3 Company Landscape
3.1 Top Remicade (Infliximab) and Biosimilar Players in Global Market
3.2 Top Global Remicade (Infliximab) and Biosimilar Companies Ranked by Revenue
3.3 Global Remicade (Infliximab) and Biosimilar Revenue by Companies
3.4 Global Remicade (Infliximab) and Biosimilar Sales by Companies
3.5 Global Remicade (Infliximab) and Biosimilar Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Remicade (Infliximab) and Biosimilar Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Remicade (Infliximab) and Biosimilar Product Type
3.8 Tier 1, Tier 2 and Tier 3 Remicade (Infliximab) and Biosimilar Players in Global Market
3.8.1 List of Global Tier 1 Remicade (Infliximab) and Biosimilar Companies
3.8.2 List of Global Tier 2 and Tier 3 Remicade (Infliximab) and Biosimilar Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type - Global Remicade (Infliximab) and Biosimilar Market Size Markets, 2022 & 2029
4.1.2 Brand
4.1.3 Biosimilar
4.2 By Type - Global Remicade (Infliximab) and Biosimilar Revenue & Forecasts
4.2.1 By Type - Global Remicade (Infliximab) and Biosimilar Revenue, 2018-2023
4.2.2 By Type - Global Remicade (Infliximab) and Biosimilar Revenue, 2024-2029
4.2.3 By Type - Global Remicade (Infliximab) and Biosimilar Revenue Market Share, 2018-2029
4.3 By Type - Global Remicade (Infliximab) and Biosimilar Sales & Forecasts
4.3.1 By Type - Global Remicade (Infliximab) and Biosimilar Sales, 2018-2023
4.3.2 By Type - Global Remicade (Infliximab) and Biosimilar Sales, 2024-2029
4.3.3 By Type - Global Remicade (Infliximab) and Biosimilar Sales Market Share, 2018-2029
4.4 By Type - Global Remicade (Infliximab) and Biosimilar Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Remicade (Infliximab) and Biosimilar Market Size, 2022 & 2029
5.1.2 Ankylosing Spondylitis
5.1.3 Rheumatoid Arthritis
5.1.4 Crohn’s Disease
5.1.5 Other
5.2 By Application - Global Remicade (Infliximab) and Biosimilar Revenue & Forecasts
5.2.1 By Application - Global Remicade (Infliximab) and Biosimilar Revenue, 2018-2023
5.2.2 By Application - Global Remicade (Infliximab) and Biosimilar Revenue, 2024-2029
5.2.3 By Application - Global Remicade (Infliximab) and Biosimilar Revenue Market Share, 2018-2029
5.3 By Application - Global Remicade (Infliximab) and Biosimilar Sales & Forecasts
5.3.1 By Application - Global Remicade (Infliximab) and Biosimilar Sales, 2018-2023
5.3.2 By Application - Global Remicade (Infliximab) and Biosimilar Sales, 2024-2029
5.3.3 By Application - Global Remicade (Infliximab) and Biosimilar Sales Market Share, 2018-2029
5.4 By Application - Global Remicade (Infliximab) and Biosimilar Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region - Global Remicade (Infliximab) and Biosimilar Market Size, 2022 & 2029
6.2 By Region - Global Remicade (Infliximab) and Biosimilar Revenue & Forecasts
6.2.1 By Region - Global Remicade (Infliximab) and Biosimilar Revenue, 2018-2023
6.2.2 By Region - Global Remicade (Infliximab) and Biosimilar Revenue, 2024-2029
6.2.3 By Region - Global Remicade (Infliximab) and Biosimilar Revenue Market Share, 2018-2029
6.3 By Region - Global Remicade (Infliximab) and Biosimilar Sales & Forecasts
6.3.1 By Region - Global Remicade (Infliximab) and Biosimilar Sales, 2018-2023
6.3.2 By Region - Global Remicade (Infliximab) and Biosimilar Sales, 2024-2029
6.3.3 By Region - Global Remicade (Infliximab) and Biosimilar Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country - North America Remicade (Infliximab) and Biosimilar Revenue, 2018-2029
6.4.2 By Country - North America Remicade (Infliximab) and Biosimilar Sales, 2018-2029
6.4.3 US Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.4.4 Canada Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.4.5 Mexico Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.5 Europe
6.5.1 By Country - Europe Remicade (Infliximab) and Biosimilar Revenue, 2018-2029
6.5.2 By Country - Europe Remicade (Infliximab) and Biosimilar Sales, 2018-2029
6.5.3 Germany Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.5.4 France Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.5.5 U.K. Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.5.6 Italy Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.5.7 Russia Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.5.8 Nordic Countries Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.5.9 Benelux Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.6 Asia
6.6.1 By Region - Asia Remicade (Infliximab) and Biosimilar Revenue, 2018-2029
6.6.2 By Region - Asia Remicade (Infliximab) and Biosimilar Sales, 2018-2029
6.6.3 China Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.6.4 Japan Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.6.5 South Korea Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.6.6 Southeast Asia Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.6.7 India Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.7 South America
6.7.1 By Country - South America Remicade (Infliximab) and Biosimilar Revenue, 2018-2029
6.7.2 By Country - South America Remicade (Infliximab) and Biosimilar Sales, 2018-2029
6.7.3 Brazil Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.7.4 Argentina Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country - Middle East & Africa Remicade (Infliximab) and Biosimilar Revenue, 2018-2029
6.8.2 By Country - Middle East & Africa Remicade (Infliximab) and Biosimilar Sales, 2018-2029
6.8.3 Turkey Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.8.4 Israel Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.8.5 Saudi Arabia Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
6.8.6 UAE Remicade (Infliximab) and Biosimilar Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 J & J
7.1.1 J & J Company Summary
7.1.2 J & J Business Overview
7.1.3 J & J Remicade (Infliximab) and Biosimilar Major Product Offerings
7.1.4 J & J Remicade (Infliximab) and Biosimilar Sales and Revenue in Global (2018-2023)
7.1.5 J & J Key News & Latest Developments
7.2 Pfizer
7.2.1 Pfizer Company Summary
7.2.2 Pfizer Business Overview
7.2.3 Pfizer Remicade (Infliximab) and Biosimilar Major Product Offerings
7.2.4 Pfizer Remicade (Infliximab) and Biosimilar Sales and Revenue in Global (2018-2023)
7.2.5 Pfizer Key News & Latest Developments
7.3 Organon
7.3.1 Organon Company Summary
7.3.2 Organon Business Overview
7.3.3 Organon Remicade (Infliximab) and Biosimilar Major Product Offerings
7.3.4 Organon Remicade (Infliximab) and Biosimilar Sales and Revenue in Global (2018-2023)
7.3.5 Organon Key News & Latest Developments
7.4 Amgen
7.4.1 Amgen Company Summary
7.4.2 Amgen Business Overview
7.4.3 Amgen Remicade (Infliximab) and Biosimilar Major Product Offerings
7.4.4 Amgen Remicade (Infliximab) and Biosimilar Sales and Revenue in Global (2018-2023)
7.4.5 Amgen Key News & Latest Developments
8 Global Remicade (Infliximab) and Biosimilar Production Capacity, Analysis
8.1 Global Remicade (Infliximab) and Biosimilar Production Capacity, 2018-2029
8.2 Remicade (Infliximab) and Biosimilar Production Capacity of Key Manufacturers in Global Market
8.3 Global Remicade (Infliximab) and Biosimilar Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Remicade (Infliximab) and Biosimilar Supply Chain Analysis
10.1 Remicade (Infliximab) and Biosimilar Industry Value Chain
10.2 Remicade (Infliximab) and Biosimilar Upstream Market
10.3 Remicade (Infliximab) and Biosimilar Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Remicade (Infliximab) and Biosimilar Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
LED Light-Up Blanket Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 116 |
Pelvic Floor Functional Magnetic Stimulator Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 115 |
Multi-Modality Biofeedback System Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 112 |
High Frequency Evaluation and Therapy Device Market, Global Outlook and Forecast 2023-2029
| Price : US $3250 | Date : May 2023 |
| CAT ID : 7 | Pages : 115 |
Choose License Type
Why Choose Us ?
24/7 Research support
Quality assurance
Information security
The report efficiently evaluates the market from various dimensions to deliver an
end-product that is informative, elaborate, and accurate and includes detailed
market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast.
The market was valued at xx Million US$ in 2019, and is expected to grow at a CAGR of
xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the
industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by Types, Applications, Technology, End-use Industries, and Regions.
The report presents the current market size, and market forecast, market
opportunities, key drivers and restraints, regulatory scenario, industry trend, PESTLE
analysis, PORTER’s analysis, new product approvals/launch, promotion and marketing
initiatives, pricing analysis, competitive landscape which help businesses in
decision making. The analysis data is based on current and historical market trends
which help in investment related decisions.
Custom research is crucial components of the business strategy which helps any
organization to gain insight into specific business sector, aligned with specific area
of interest. Thus, SMI offers more accurate, pragmatic, and actionable information
specifically tailored to suit your business needs.
